Lisata Therapeutics Inc (LSTA)

[Viperciara]

Betting On Cancer Treatment? Keep An Eye On This Company





Ritesh Anan , Benzinga Staff Writer Follow

May 26, 2015 3:02pm



Betting On Cancer Treatment? Keep An Eye On This Company


Related NBS

NeoStem's Lead Immuno-Oncology Product Candidate, NBS20, Receives ATMP Classification From the European Medicines Agency

NeoStem Announces Expanded Cell Therapy Manufacturing Relationship With Kite Pharma






NeoStem Inc NBS recently received a grant of $17.7 million to fund the company's effort in research of cell therapy products for cancer from California Institute of Regenerative Medicine. Following the announcement of the grant, shares of NeoStem rose by over 20 percent.

NeoStem CEO Dr. David Mazzo was on Fox Business News recently to talk about the company's new cancer drug.

NBS20

"Our product is called NBS20; it's too early for it to have a name, but it's in late-stage clinical development," Mazzo said.

"It works by actually identifying within a cancer those cancer stem cells that proliferate and teaching the immune system to actually kill those selectively. So, it's a way to prolong survival in a way that no other treatment does."

Related Link: New Drug Could Transform Pancreatic Cancer Treatment

A Simple Procedure

On how the therapy would be delivered, Mazzo said, "It's actually quite simple. This is what many people call a cancer vaccine.

"So, it's administered as a subcutaneous injection. It's a very simple procedure to administer the drug, a little injection under the skin once a week for three weeks and then once a month for five months and that's it."

The Grant

Mazzo was asked about the kind of results the company got for NBS20 that led it to being awarded the $17.7 million grant. He replied, "We actually generated really phenomenal results and two phase-II trials and the most recent of those two was a controlled, randomized study where the patients received our treatment had a 72 percent survival rate at two years in comparison to a control group, which only had a 31 percent. And even in that study, that control group was an active control.

"So, the historical norm for those patients would have been a 25 percent survival rate. So, really a remarkable prolongation of life," Mazzo said.

Image Credit: Public Domain

.


Read more: http://www.benzinga.com/general/health-care/15/05/5537123/betting-on-cancer-treatment-keep-an-eye-on-this-company#ixzz3bKHRoPNP